23andMe raises $115M in Series E round; Judge reduces Boston Sci legal liability by $90M;

@FierceMedDev: Abbott's bioresorbable stent meets primary endpoint, but NEJM editorial raises questions. Story | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Clinicians criticize Baxter for suspending comparative drug/device heart failure trial. Article | Follow @VarunSaxena2

@EmilyWFierce: Pigeons, other birds, lizards...there's a full menagerie at an Indian API maker's facilities. FiercePharmaManufacturing report | Follow @EmilyWFierce

> Consumer-oriented diagnostic and genetics company 23andMe raised $115 million in a Series E round led Fidelity Management & Research Company, with participation from Illumina ($ILMN), New Enterprise Associates, MPM Capital, and Google Ventures. More

> Boston Scientific ($BSX) scored a (partial) legal victory, for a Delaware court reduced a $100 million verdict award to a woman who claimed to be injured from the company's transvaginal mesh to $10 million. Boston Scientific had requested the original verdict to be set aside in favor of a new trial, but it was denied. The company will appeal the decision. More

> Toronto's Figure 1 raised $5 million in a VC round to expand sales of its smartphone app that enables clinicians to share medical images. It will use the money to usable in additional languages, including Brazilian Portuguese, Spanish and Chinese. More

> The FDA cleared a NFANT Labs' smart baby bottle. The device measures a premature infant's tongue strength to determine the optimal time for transitioning from tube feeding to bottle or breast feeding. More

Biotech News

@FierceBiotech: 5 experts, 1 voice: Biotech bubble? It's different this time. Editor's corner | Follow @FierceBiotech

@JohnCFierce: put out a "no comment" after its stock had dropped >50% in 2 days. That kind of zombie strategy is a disaster. | Follow @JohnCFierce

> Lilly and Incyte's oral arthritis drug tops Humira in a big Phase III trial. Article

> Roche backs €19M round to move Minoryx's CNS drug into the clinic. Story

> Moderna's top scientist steps down amid a billion-dollar R&D push. Article

Pharma News

@FiercePharma: Vaccine-derived polio case raises ugly head in Laos. FiercePharmaAsia article | Follow @FiercePharma

@EricPFierce: Have to wonder if FDA issues with PharMEDium played into investment firm's decision to sell. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: $MYL CFO on lack of other bidders for $PRGO: "The silence is deafening." | Follow @CarlyHFierce

> Can J&J's Invokana reap the benefits of Lilly and BI's new cardiac data? Its CFO thinks so. Article

> J&J says it has plenty of firepower for M&A, buyback or no buyback. News

Biotech Research News

> Gene therapy protects neurons in Parkinson's disease mouse study. More

> A promising MEK inhibitor in mice loses some luster in human trials. Report

> Gene therapy study in dogs demonstrates success in preserving vision. Story

> Preclinical research often hypes cancer drugs. Item

> Penn investigators finger a 'turncoat' molecule's key role in Tykerb resistance. Article

Pharma Marketing News

> Merck KGaA hopes to spiff up its image with new logo, fewer names. Story

> GSK scores a Part D exclusive for slow-starting lung meds Incruse, Anoro. Report

> With latest hires, Klick sees sign of more creative times in pharma marketing. More

> Influential cancer group to add drug-cost data to its treatment advice. Story

> AbbVie's Humira, J&J's Invokana lead September's $231M in pharma TV ad spending. Article

Vaccines News

> MedImmune joins GSK, Vanderbilt U in Human Vaccines Project. Story

> Reports: Chinese firm to spend $315M on Ebola vaccine manufacturing plant. More

> University of Maryland HIV vaccine candidate enters human trials. News

> Immunomic licenses allergy vaccine tech to Astellas for $300M. Report

> Pfizer touts Trumenba immunogenicity when administered with Menactra, Adacel. Story